Anticoagulation And Kidney Disease

Zahra Shafii, MD. Assistant Professor of Nephrology Rajaie Cardiovascular Medical and Research Center IUMS



Outline

- Anticoagulation in CKD
- Anticoagulation in Nephrotic Syndrome
- Anticoagulation in Hemodialysis
- Anticoagulation in Kidney Transplantation
- Bleeding Management of Anticoagulants
- Anticoagulation Related Nephropathy



Anticoagulation in CKD



- Patients with chronic kidney disease are at increased risk for both arterial and venous thromboembolism
- The risk of AF and ACS is double in patients with eGFR <60 mL/min/1.73m
- Anticoagulants are cleared, with only a few exceptions, by kidneys and/or the liver



Vitamin K Antagonists

- VKAs are most widely used
- There is an Increased hemorrhagic risk in CKD particularly within the first 30 to 90 days
- Most major bleeding events are GI
- The guidelines for AF or VTE: no dose adjustment in CKD
- Start-low go-slow" rule to prevent the risk of hemorrhage reduce warfarin doses by 10% if eGFR: 30 and 59 and by 20% if eGFR < 30
- There is a relationship between warfarin-vascular calcifications and renal function decline.



Heparin

	Dose adjustment function of eGFR (mL/min)			
Anticoagulant	59-30	29-15	<15	
Unfractionated heparin	Not necessary	Not necessary	Dose reduction by 33%: loading dose 60 IU/kg, maintenance 12 IU/kg/h, subsequent aPTT-adjusted dosing	
Enoxaparin	Not necessary (1 mg/kg/12 hours) VTE 1.5 mg/kg once daily (The United States)	1 mg/kg once daily anti-Xa adjusted dosing (Anti- Xa:Iia ratio 3.9)		
Dalteparin	ACS (120 IU/kg/12 hours) VTE (100 IU/kg/12 hours or 200 IU/kg once daily 1 month, then 150 IU/kg once daily 5 months, then oral anticoagulants/LMWH)	-		
Tinzaparin	VTE (175 IU/kg once daily)		justed dosing to eGFR Xa:Iia ratio 2.8)	
Fondaparinux	VTE: 50% dose compared to the recommended dose per body weight ACS 2.5 mg once daily	<30	recommended for eGFR	

DOACs

Dabigatran: FDA approval 2010
Rivaroxaban: FDA approval in 2011
Apixaban: FDA approval in late 2012
Edoxaban: FDA approval in early 2015



Potential advantages and disadvantages of DOACs

Potential advantages	Potential disadvantages	
Lower rates of intracranial bleed and hemorrhagic strokes than warfarin	Higher drug cost; may require prior insurance approval	
No need for routine lab monitoring	Lack of availability of a reversal agent	
Fewer drug or food interactions than	Increased risk of gastrointestinal bleeding	
warfarin	Higher rebound rate of VTE events in patients with poor adherence	
	No clear efficacy data in certain patient populations (e.g., patients with malignancy)	



DOACs cont...

- Main issue :define kidney function
- 60% of the patients with mild-to-moderate CKD receive lower doses of DOACs, (increased thromboembolic events).
- Check renal function : initiation of treatment with DOACs, after 3 months, and then every year
- Check RF, in high-risk patients (elderly >75 years, women, patients with low body mass, frail or on dabigatran) : every 6 months
- Check RF in Any condition worsening RF :infections, acute heart failure, potentially nephrotoxic medication



Evidence for use of anticoagulant class according to renal function

eGFR	UFH	LMWHs	Warfarin	Direct oral anticoagulants	
(mL/min)					
>90	Yes	Yes	Yes	Yes	
60-89	Yes	Yes	Yes	Yes	
30-59	Yes	Yes	Yes	Rivaroxaban dose adjustment	
15-29	Yes	Dose adjustments may be needed; bioaccumulation possible	Yes	Rivaroxaban and dabigatran contraindicated	
		Enoxaparin use with caution		Apixaban use with caution	
<15	Yes	Use contraindicated outside selected patients with appropriate monitoring	Yes	Rivaroxaban and dabigatran contraindicated; see text for discussion of apixaban	

Yes indicates there is evidence for use without dose adjustment.



Pharmacokinetic properties of oral anticoagulants (adapted from Jain et al¹³ and Lutz et al¹⁴)

			Pharmacokinetic properties		
Oral	Mashanism of action	Duoduura	Matabaliam	Diskurable	Dose
anticoaguiant	Mechanism of action	Prodrug	Metabolism	Dialyzable	adjustment
Warfarin	Vitamin K antagonist	No	Predominantly via cytochrome P450 type 2C9 (CYP2C9)	No	No
Dabigatran	Direct inhibitor of free thrombin and fibrin-bound thrombin	Yes	Renal excretion 80%	Yes	Yes
Rivaroxaban	Free and clot-bound Xa factor inhibitor, prothrombinase activity inhibitor	No	Renal excretion 66%, 36% as unchanged drug	No	Yes
Apixaban	Free and clot-bound Xa factor inhibitor	No	Metabolized in liver via CYP3A4, renal excretion 27% and in feces	Partial	No
Edoxaban	Free Xa factor and tissue factor inhibitor	No	10% hydrolyzed by carboxylesterase 1, 50% unchanged upon renal excretion	No	Yes



	CrCl (mL/mm) estimated using the Cockroft-Gault equation				
Recommended	≥50	30-49	15–29	<15	End-stage renal disease on dialysis
oral				Warfarin/DO	ACs (with
anticoagulant	DOACs	DOACs	Warfarin/DOACs	caution)	
Warfarin	Preferable to adjust the dose function of time in therapeutic range, op	otimal≥709	%		
Dabigatran	150 mg twice daily	Idem	The United States (based only	No	
	110 mg twice daily \geq 80 years, or associated with P-glycoprotein		on FDA approval) - 75 mg		
	inhibitors, or high risk of hemorrhage		twice daily		
			Europe - NO		
Rivaroxaban	20 mg once daily	15 n	ng once daily (dose used by	No	
		landma	rk trials recommended by small		
		ſ	harmacokinetic studies)		
Apixaban	5 mg twice daily	Idem	2.5 mg twice daily	The United	The United
	2.5 mg twice daily if any ${\geq}2$ of the following: age ${\geq}$ 80 years, body			States - 2.5	States (FDA) -
	weight \leq 60 kg and creatinine \geq 1.5 mg/dL			mg twice	5 mg twice
				daily	daily
				Europe - NO	Europe - NO
Edoxaban	60 mg once daily	30 mg or	nce daily	No	
	30 mg once daily when \geq 2 of the following criteria are met: body				
	weight \leq 60 kg, CrCl 30-50 mL/min and therapy with Verapamil,				
	Dronedarone or Quinidine is associated				

CrCl (mL/min) estimated using the Cockroft-Gault equation

SAMe-TT2R₂ Score

Sex	Female gender		
Age	Age < 60 years old		
Medical history	Two or more co-morbidities: • Hypertension • Diabetes • Coronary disease • Peripheral artery disease • Heart failure • Prior stroke • Pulmonary disease • Renal disease • Liver disease		
Treatment	Treatment with amiodarone		
Tobacco		Tobacco use in the past 2 years	
Race		Non-Caucasian race	
Maximum points			i

Anticoagulation in Nephrotic Syndrome



- NS carry clinically significant risk of arterial and venous thromboembolic events especially in patients with membranous nephropathy.
- Anticoagulation should be considered in the setting of hypoalbuminemia.
- Must be balanced with the patient's risk of bleeding.
- It should be commenced as soon as it is safe as the risk of thrombosis is highest in the first 6 months of diagnosis.



- Etiology of NS
- Serum Albumin level
- Risk of bleeding
- Other VTE risk factors: immobility, obesity, malignancy, recent surgery, pregnancy, medications, central venous catheters, or genetic




- Anticoagulation is not beneficial for patients with high bleeding risk scores, regardless of serum albumin.
- the HAS-BLED scoring may not be accurate, particularly in severe hypoalbuminemia



Clinical characteristics comprising the HAS-BLED bleeding risk score

Letter	Clinical characteristic*	Points
н	Hypertension (ie, uncontrolled blood pressure)	1
А	Abnormal renal and liver function (1 point each)	1 or 2
S	Stroke	1
В	Bleeding tendency or predisposition	1
L	Labile INRs (for patients taking warfarin)	1
E	Elderly (age greater than 65 years)	1
D	Drugs (concomitant aspirin or NSAIDs) or excess alcohol use (1 point each)	1 or 2
		Maximum 9 points
HAS-BLED score (total points)	Bleeds per 100 patient-years¶	
0	1.13	
1	1.02	
2	1.88	
3	3.74	
4	8.70	
5 to 9	Insufficient data	

The HAS-BLED bleeding risk score has only been validated in patients with atrial ribrillation receiving warfarin. Refer to UpToDate topics on anticoagulation in patients with atrial fibrillation



- Choice of agent due to patient and clinical factors: ease of use and access, patient preference, and feasibility of monitoring requirements.
- DOACs: not first-line for prophylaxis and treatment of ATE/VTE in NS
- DOACs: reasonable alternatives to warfarin and LMWH in failure or intolerability of them
- Aspirin: higher albumin levels, high risk of ATE/VTE with high bleeding risk, Other (non MN) high-risk GNs



Duration of Treatment

- Optimal duration of treatment is poorly established.
- The KDIGO guidelines suggest continuation of prophylaxis while the patient remains nephrotic (serum albumin <30 g/l)



Anticoagulation in Hemodialysis



The risk of bleeding exceeds the risk of clotting in:

- Severe thrombocytopenia (platelet count of <20,000 x 10⁹/L)
- Evidence of active bleeding from the gastrointestinal tract, intra-abdominal bleeding, extensive bleeding from surgical wounds, or catheters at the time of dialysis
- Major surgery in the prior 72 hours
- Active intracranial or extradural hemorrhage
- Use of systemic anticoagulants
- Uremic pericarditis
- Factor VII or VIII deficiency

Use of antiplatelet agents alone is not bleeding risk factor



Standard-risk patients

- UFH: 1000 to 2000 units at beginning then infusion of 500 units per hour, turned off 60, if clotting develops 30 minutes before the end
- Enoxaparin: 20 mg for a four-hour dialysis session.
- If clotting detected: increase the UFH or LMWH bolus or UFH infusion and evaluate the dialysis access
- Bleeding from needle sites longer than 7 minutes: stop infusion earlier, lower the bolus dose for the following dialysis session, evaluation of HD access



High risk for bleeding patients

- No-heparin method
- Heparinized solution rinse
- Heparin-bonded dialyzer



Recurrent filter thrombosis

Standard bleeding risk:

✓ Dose adjustment of UFH or LMWH

• High bleeding risk:

✓ Increase the blood flow rate and the needle gauge,

- Converting to short daily HDF with a high volume of predilutional infusate
- More frequent saline flushes

✓ Citrate dialysate



Anticoagulation in Kidney Transplantation



Pre operation

- Warfarin:
 - Stopping 5 days before a planned or utilizing a reversal agent (FFP or PCCs)
- DOACs:
 - Discontinuation for two drug half-lives
 - Utilize with caution of in patients awaiting deceaseddonor transplantation



Elimination half-life based on renal function

Renal insufficiency	Half-life (h)			
Dabigatran ^{3,12,72}				
CLcr>80 mL/min	13.8			
CLcr 50-79 mL/min	16.6			
CLcr 30-49 mL/min	18.7			
CLcr <30 mL/min	27.5			
Hemodialysis	34.1			
Rivaroxaban ^{3,23,24,72}				
CLcr >80 mL/min	8.3			
CLcr 50-79 mL/min	8.7			
CLcr 30-49 mL/min	9.0			
CLcr <30 mL/min	9.5			
Hemodialysis	12-13			

Apixaban^{3,33,34,72}

CLcr >80 mL/min	15.1
CLcr 50-79 mL/min	14.6
CLcr 30-49 mL/min	17.6
CLcr <30 mL/min	17.3
Hemodialysis	12.5/12.7ª

Edoxaban^{37,38}

CLcr>80 mL/min	8.6
CLcr 50-79 mL/min	8.6
CLcr 30-49 mL/min	9.4
Clcr <30 mL/min	16.9
Hemodialysis	10–14 ^{<u>b</u>}

110

Original article

Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single-center cohort study

Alexandra L. Bixby 📉, Suhail A Shaikh, Abhijit S. Naik, Laura Cotiguala, Katie McMurry, Milagros D. Samaniego-Picota, Vincent D. Marshall, Jeong M. Park

First published: 27 February 2020 | https://doi.org/10.1111/tri.13599

Direct oral anticoagulant considerations in solid organ transplantation: A review

David M. Salerno,¹ Demetra Tsapepas,^{1,2} Apostolos Papachristos,³ Jae-Hyung Chang,⁴ Spencer Martin,⁵ Mark A. Hardy,² and Jaclyn McKeen⁶

Author information
Copyright and License information Disclaimer

After Transplantion

- DOACs should be started when hemostasis effectively achieved, with approval of the transplant surgeon.
- Avoid the use of DOACs in the immediate post-transplant period until a stable renal allograft function, especially in deceased-donor kidney transplants and in highimmunological risk kidney



DOACs in Renal Transplant

- Metabolism of the DOACs is dependent on the CYP 450 enzyme system and P-gp efflux pump
- Dabigatran is a substrate of P-gp efflux pump. With no contribution from CYP 450
- The choice of tacrolimus for immunosuppression may be favorable compared to CsA
- 50% dose decrease when coadministered with drugs that are strong dual-inhibitors including ketoconazole, itraconazole, ritonavir, or clarithromycin



Drug Interactions with Direct Oral Anticoagulants

	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Increased	Strong p-gp inhibitors:	Strong CYP3A4	Strong	Strong p-gp
concentration	ketoconazole,	and p-gp	CYP3A4 and	inhibitors:
	ciclosporin, tacrolimus,	inhibitors:	p-gp inhibitors:	reduce dose
	ritonavir, dronedarone	ketoconazole,	ketoconazole,	with
	Caution with:	ritonavir,	ritonavir,	ketoconazole,
	amiodarone, verapamil,	dronedarone	dronedarone	ciclosporin,
	clarithromycin,	Caution with:		dronedarone
	quinidine, ticagrelor	ciclosporin,		Caution with:
		tacrolimus		ritonavir
Reduced	Strong p-gp inducers:	Strong CYP3A4	Strong	Strong p-gp
concentration	rifampicin, St John's	and p-gp CYP3A4 and	inducers:	
	wort, carbamazepine,	inducers:	p-gp inducers:	rifampicin, St
	phenytoin, barbiturates,	rifampicin, St	rifampicin, St	John's wort,
	dexamethasone	John's wort,	John's wort,	carbamazepine,
		carbamazepine,	carbamazepine,	phenytoin,
		phenytoin,	phenytoin,	barbiturates,
		barbiturates	barbiturates	dexamethasone



Bleeding Management of Anticoagulants






- Assess the severity of bleeding Minor bleeding Major bleeding
- Assess and the degree of anticoagulation drug dose, last dose



- Discontinue the drug
- Transfuse blood products if necessary
- Address the hemorrhage anatomically
- Administer pro-hemostatic therapies such as antifibrinolytic agents
- Use Antidote



Management of Patients in Cases of Bleeding



• Dabigatran:

Idarucizumab, aPCC, antifibrinolytic agent, oral activated charcoal if the last anticoagulant dose was within the previous two hours, Hemodialysis

Rivaroxaban, apixaban, edoxaban, betrixaban

An antifibrinolytic agent, oral activated charcoal if the last dose of the anticoagulant was recent enough (rivaroxaban 8 hours; apixaban 6 hours; edoxaban 2 hours), and exanet alfa, unactivated 4-factor PCC



Anticoagulation Related Nephropathy



- A type of AKI by excessive anticoagulation with warfarin and other anticoagulants
- Can cause CKD and increase risk of mortality



Risk Factors

- moderate or severe anticoagulation induced anticoagulants:(INR >4) major risk factor
- Underlying chronic kidney disease
- Diabetes mellitus
- Heart failure
- Hypertension
- Glomerulonephritis particularly nephrotic syndrome



Clinical Presentation

- AKI within several days of elevated INR.
- Microscopic or gross hematuria that may be transient
- No characteristic features on imaging




SUSPECT when the following clinical findings are present:

- · Hematuria (without clots) combined with AKI or worsening of a known CKD
- Treatment with warfarin (or other novel oral anti-coagulants) started before the onset of hematuria and AKI
- Increase in prothrombin INR above 3.0 IU (warfarin-treated patients only)
- No record of acute haemorrhage
- Exclude other causes of AKI and hematuria (e.g. acute glomerulonephritis, vasculitis, athero-embolic disease, drug hypersensitivity)

CONFIRM diagnosis by kidney biopsy (after normalization of INR) demonstrating:

- Presence of dysmorphic erythrocytes in Bowman's space (by electron microscopy or other means)
- Extensive erythrocyte cast formation in distal nephron segments (not containing Tamm-Horsfall mucoprotein)
- Acute tubule cell injury with intra-cytoplasmic tubular ferric iron/hemosiderin deposits (Perl's Prussian Blue stain)
- Absence of endo-capillary or extra-capillary proliferative glomerulonephritis (mesangial deposition of IgA, IgG or IgM by IF may be present)
- Other causes of AKI and hematuria in an anti-coagulated patient (e.g. athero-embolic disease) have been excluded



TREATMENT

- Prevent ARN: proper adjustment of the anticoagulant dose.
- In warfarin-treated Pt.: switch to dabigatran_or rivaroxaban
- In Pt. receiving dabigatran ,rivaroxaban: reduce the dose
- In Pt. receiving apixaban: switch to rivaroxaban, dabigatran



Thank You

